Cooper Companies (NASDAQ:COO) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Cooper Companies (NASDAQ:COO) from a hold rating to a buy rating in a research report released on Friday.

COO has been the topic of a number of other research reports. Morgan Stanley boosted their price objective on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Stifel Nicolaus reissued a “buy” rating and set a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Robert W. Baird upped their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, August 29th. Finally, Piper Sandler raised their price target on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Stock Performance

NASDAQ:COO traded up $0.42 during midday trading on Friday, reaching $103.75. The stock had a trading volume of 679,183 shares, compared to its average volume of 1,167,679. The stock has a market cap of $20.66 billion, a P/E ratio of 57.80, a P/E/G ratio of 2.24 and a beta of 0.99. Cooper Companies has a 12-month low of $80.48 and a 12-month high of $112.38. The firm has a fifty day simple moving average of $107.30 and a two-hundred day simple moving average of $97.54. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. During the same quarter last year, the firm posted $0.84 earnings per share. Cooper Companies’s revenue was up 7.8% on a year-over-year basis. On average, equities analysts expect that Cooper Companies will post 3.65 EPS for the current year.

Insider Buying and Selling at Cooper Companies

In other news, COO Daniel G. Mcbride sold 114,992 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now owns 44,696 shares of the company’s stock, valued at $4,714,534.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, COO Daniel G. Mcbride sold 114,992 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at $4,714,534.08. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Brian G. Andrews sold 24,788 shares of Cooper Companies stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $105.90, for a total value of $2,625,049.20. Following the completion of the sale, the chief financial officer now directly owns 6,614 shares of the company’s stock, valued at approximately $700,422.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 256,373 shares of company stock worth $27,637,427. 2.00% of the stock is currently owned by company insiders.

Institutional Trading of Cooper Companies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Citizens Financial Group Inc. RI boosted its stake in shares of Cooper Companies by 11.7% during the third quarter. Citizens Financial Group Inc. RI now owns 6,588 shares of the medical device company’s stock valued at $727,000 after purchasing an additional 688 shares during the period. Advisors Asset Management Inc. boosted its holdings in Cooper Companies by 24.6% in the third quarter. Advisors Asset Management Inc. now owns 34,639 shares of the medical device company’s stock worth $3,822,000 after acquiring an additional 6,839 shares in the last quarter. Segall Bryant & Hamill LLC grew its holdings in shares of Cooper Companies by 21.5% during the third quarter. Segall Bryant & Hamill LLC now owns 106,421 shares of the medical device company’s stock valued at $11,742,000 after buying an additional 18,839 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Cooper Companies during the 3rd quarter valued at $1,154,000. Finally, Tranquility Partners LLC boosted its stake in Cooper Companies by 7.1% during the 3rd quarter. Tranquility Partners LLC now owns 9,341 shares of the medical device company’s stock valued at $1,031,000 after purchasing an additional 620 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.